Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathway

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Stevenson, Leanne ^a   Allen, Wendy L ^a   Proutski, Irina ^a   Stewart, Gail ^a   Johnston, Louise ^a   McCloskey, Karen ^a   Wilson, Peter M ^a   Longley, Daniel B ^a   Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALBINDIN; CALBINDIN 2; CYTOCHROME C; FLUOROURACIL; MESSENGER RNA; PROTEIN P53; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CASPASE 9; SMALL INTERFERING RNA; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL STRAIN HCT116; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; GENE SILENCING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL SURVIVAL; COLORECTAL TUMOR; DNA MICROARRAY; DRUG EFFECT; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASE 7; CASPASE 9; CELL SURVIVAL; COLORECTAL NEOPLASMS; CYTOCHROMES C; FLUOROURACIL; HCT116 CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 79956361813     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020276     Document Type: Article

References (31)

1. Johnston PG, Kaye S, (2001) Capecitabine: A novel agent for the treatment of solid tumors. Anticancer Drugs 12: 639-46 doi:10.1097/00001813-200109000-00001.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355: 1041-1047 doi:10.1016/S0140-6736(00)02034-1.
3. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, et al. (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147.
4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345 doi:10.1056/NEJMoa033025.
5. Caponigro F, Formato R, Caraglia M, Normanno N, Iaffaioli RV, (2005) Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr Opin Oncol 17: 212-217 doi:10.1097/01.cco.0000159623.68506.cf.
6. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, et al. (2005) Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508 doi:10.1200/JCO.2005.10.017.
7. Hack NJ, Wride MC, Charters KM, Kater SB, Parks TN, (2000) Developmental changes in the subcellular localization of calretinin. J Neurosci 20: RC67.
8. Schwaller B, Durussel I, Jermann D, Herrmann B, Cox JA, (1997) Comparison of the Ca2+-binding properties of human recombinant calretinin-22k and calretinin. J Biol Chem 272: 29663-29671 doi:10.1074/jbc.272.47.29663.
9. Bertschy S, Genton CY, Gotzos V, (1998) Selective immunocytochemical localisation of calretinin in the human ovary. Histochem Cell Biol 109: 59-66 doi:10.1007/s004180050202.
10. Gotzos V, Wintergerst ES, Musy JP, Spichtin HP, Genton CY, (1999) Selective distribution of calretinin in adenocarcinomas of the human colon and adjacent tissues. Am J Surg Pathol 23: 701-711 doi:10.1097/00000478-199906000-00010.
11. Gotzos V, Schwaller B, Gander JC, Bustos-Castillo M, Celio MR, (1996) Heterogeneity of expression of the calcium-binding protein calretinin in human colonic cancer cell lines. Anticancer Res 16: 3491-3498.
12. Doglioni C, Tos AP, Laurino L, Iuzzolino P, Chiarelli C, et al. (1996) Calretinin: A novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 20: 1037-1046 doi:10.1097/00000478-199609000-00001.
13. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ, (2005) Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 18: 105-110 doi:10.1038/modpathol.3800259.
14. Schurmans S, Schiffmann SN, Gurden H, Lemaire M, Lipp HP, et al. (1997) Impaired long-term potentiation induction in dentate gyrus of calretinin-deficient mice. Proc Natl Acad Sci U S A 94: 10415-10420 doi:10.1073/pnas.94.19.10415.
15. Boehning D, Patterson RL, Sedaghat L, Glebova NO, Kurosaki T, et al. (2003) Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis. Nat Cell Biol 5: 1051-1061 doi:10.1038/ncb1063.
16. Mattson MP, Chan SL, (2003) Calcium orchestrates apoptosis. Nat Cell Biol 5: 1041-1043 doi:10.1038/ncb1203-1041.
17. Wu Y, Fabritius M, Ip C, (2009) Chemotherapeutic Sensitization by Endoplasmic Reticulum Stress: Increasing the Efficacy of Taxane Against Prostate Cancer. Cancer Biol Ther 2009 January; 8: 146-152.
18. Boyer J, Allen WL, McLean EG, Wilson PM, McCulla A, et al. (2006) Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 66: 2765-2777 doi:10.1158/0008-5472.CAN-05-2693.
19. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, et al. (2006) c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25: 838-848 doi:10.1038/sj.onc.1209122.
20. Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, et al. (2004) Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 10: 2158-2167 doi:10.1158/1078-0432.CCR-03-0362.
21. Staub E, Groene J, Heinze M, Mennerich D, Roepcke S, et al. (2009) An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types. J Mol Med 87: 633-644.
22. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, et al. (2008) A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 14: 1744-1752.
23. Longley DB, Boyer J, Allen WL, Latif T, Ferguson PR, et al. (2002) The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res 62: 2644-2649.
24. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, et al. (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263-269.
25. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B, (2000) Role of BAX in the apoptotic response to anticancer agents. Science 290: 989-992 doi:10.1126/science.290.5493.989.
26. Wilson TR, McEwan M, McLaughlin K, Le Clorennec C, Allen WL, et al. (2009) Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells. Oncogene 28: 63-72 doi:10.1038/onc.2008.366.
27. Liston P, Fong WG, Korneluk RG, (2003) The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22: 8568-8580 doi:10.1038/sj.onc.1207101.
28. D'Orlando C, Fellay B, Schwaller B, Salicio V, Bloc A, et al. (2001) Calretinin and calbindin D-28k delay the onset of cell death after excitotoxic stimulation in transfected P19 cells. Brain Res 909: 145-158 doi:10.1016/S0006-8993(01)02671-3.
29. D'Orlando C, Celio MR, Schwaller B, (2002) Calretinin and calbindin D-28k, but not parvalbumin protect against glutamate-induced delayed excitotoxicity in transfected N18-RE 105 neuroblastoma-retina hybrid cells. Brain Res 945: 181-190 doi:10.1016/S0006-8993(02)02753-1.
30. Kuźnicki J, Isaacs KR, Jacobowitz DM, (1996) The expression of calretinin in transfected PC12 cells provides no protection against Ca(2+)-overload or trophic factor deprivation. Biochim Biophys Acta 1313: 194-200 doi:10.1016/0167-4889(96)00089-4.
31. Kroemer G, Reed JC, (2000) Mitochondrial control of cell death. Nat Med 6: 513-519 doi:10.1038/74994.